{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:41:45Z","timestamp":1791445305201,"version":"4.3.3"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009509","name":"Kementerian Riset Teknologi Dan Pendidikan Tinggi Republik Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009509","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020473","name":"Ministry of Research Technology and Higher Education of the Republic of Indonesia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020473","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tissue and Cell"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.tice.2026.103700","type":"journal-article","created":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T15:49:47Z","timestamp":1781711387000},"page":"103700","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Mechanistic insights into EGFR-Targeted: [\u00b9\u00b2\u2075I]I-rociletinib as a model small-molecule radioligand"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6046-2819","authenticated-orcid":false,"given":"Muammar","family":"Fawwaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muzakkir","family":"Baits","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamat","family":"Pratama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Multazam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Najib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Iriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andi Trihadi","family":"Kusuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rien","family":"Ritawidya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tice.2026.103700_bib1","doi-asserted-by":"crossref","first-page":"18","DOI":"10.21037\/atm-25-34","article-title":"Advances in personalized medicine: translating genomic insights into targeted therapies for cancer treatment","volume":"13","author":"Jamalinia","year":"2025","journal-title":"Ann. Transl. Med."},{"key":"10.1016\/j.tice.2026.103700_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17213500","article-title":"Advances in precision oncology: from molecular profiling to regulatory-approved targeted therapies","volume":"17","author":"Brlek","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.tice.2026.103700_bib3","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41577-023-00877-7","article-title":"Protein kinases: drug targets for immunological disorders","volume":"23","author":"Castelo-Soccio","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.tice.2026.103700_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176484","article-title":"Targeting oncogenic kinases: insights on FDA approved tyrosine kinase inhibitors","volume":"970","author":"Hussain","year":"2024","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.tice.2026.103700_bib5","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal. Transduct. Target. Ther."},{"key":"10.1016\/j.tice.2026.103700_bib6","doi-asserted-by":"crossref","DOI":"10.3390\/cells10051206","article-title":"Epidermal growth factor receptor expression and resistance patterns to targeted therapy in non-small cell lung cancer: a review","volume":"10","author":"Karlsen","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.tice.2026.103700_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/cells13010047","article-title":"Targeted inhibitors of EGFR: structure, biology, biomarkers, and clinical applications","volume":"13","author":"Shaban","year":"2023","journal-title":"Cells"},{"key":"10.1016\/j.tice.2026.103700_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030256","article-title":"A Radiobrominated tyrosine kinase inhibitor for EGFR with L858R\/T790M mutations in lung carcinoma","volume":"14","author":"Fawwaz","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tice.2026.103700_bib9","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.3390\/molecules25122914","article-title":"Synthesis and fundamental evaluation of radioiodinated rociletinib (CO-1686) as a probe to lung cancer with L858R\/T790M mutations of epidermal growth factor receptor (EGFR)","volume":"25","author":"Fawwaz","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.tice.2026.103700_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ph18020270","article-title":"Design, synthesis, and mechanistic anticancer evaluation of new pyrimidine-tethered compounds","volume":"18","author":"Reymova","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tice.2026.103700_bib11","volume":"2025","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.tice.2026.103700_bib12","article-title":"Current status and breakthroughs in treating advanced non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"15","author":"Hu","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.tice.2026.103700_bib13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.jmedchem.3c01502","article-title":"Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors","volume":"67","author":"Hoyt","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib14","article-title":"The advance of the third\u2011generation EGFR\u2011TKI in the treatment of non\u2011small cell lung cancer (Review)","volume":"51","author":"Cheng","year":"2024","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.tice.2026.103700_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms251810008","article-title":"Epidermal growth factor receptor tyrosine kinase inhibitors in cancer: current use and future prospects","volume":"25","author":"Dickerson","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.tice.2026.103700_bib16","article-title":"Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.tice.2026.103700_bib17","article-title":"Synthesis and initial in vitro evaluation of olmutinib derivatives as prospective imaging probe for non-small cell lung cancer","volume":"14","author":"Fawwaz","year":"2024","journal-title":"Bioimpacts"},{"key":"10.1016\/j.tice.2026.103700_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.56499\/jppres23.1743_12.2.231","article-title":"Synthesis and evaluation of a rociletinib analog as prospective imaging double mutation L858R\/T790M in non-small cell lung cancer","volume":"12","author":"Fawwaz","year":"2024","journal-title":"J. Pharm. Pharmacogn. Res."},{"key":"10.1016\/j.tice.2026.103700_bib19","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ymeth.2017.07.004","article-title":"Theranostic and nanotheranostic probes in nuclear medicine","volume":"130","author":"Drude","year":"2017","journal-title":"Methods"},{"key":"10.1016\/j.tice.2026.103700_bib20","author":"GraphPad Prism","year":"2019"},{"key":"10.1016\/j.tice.2026.103700_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108689","article-title":"Fluorenyl-phthalimide hybrids as potent aldose reductase inhibitors with selective anticancer activity: rational design, synthesis, and molecular insights","volume":"163","author":"Gundogdu","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118416","article-title":"Phthalimide-benzoic acid hybrids as potent aldose reductase inhibitors: synthesis, enzymatic kinetics, and in silico characterization","volume":"131","author":"Hoti","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib23","doi-asserted-by":"crossref","first-page":"7246","DOI":"10.1080\/07391102.2020.1803967","article-title":"Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2","volume":"39","author":"Khelfaoui","year":"2021","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.tice.2026.103700_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108788","article-title":"N-substituted phthalimide-carboxylic acid hybrids as dual-targeted aldose reductase inhibitors: synthesis, mechanistic insights, and cancer-relevant profiling","volume":"163","author":"Zognjani","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2024.108134","article-title":"Targeting cyclin-dependent kinase 2 CDK2: Insights from molecular docking and dynamics simulation - A systematic computational approach to discover novel cancer therapeutics","volume":"112","author":"Chagaleti","year":"2024","journal-title":"Comput. Biol. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1039\/D4MD00617H","article-title":"Novel benzenesulfonamides containing a dual triazole moiety with selective carbonic anhydrase inhibition and anticancer activity","volume":"16","author":"Buza","year":"2025","journal-title":"RSC Med. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib27","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13045-022-01311-6","article-title":"Emerging strategies to overcome resistance to third-generation EGFR inhibitors","volume":"15","author":"Shi","year":"2022","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.tice.2026.103700_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.gmg.2025.100064","article-title":"A comprehensive comparison of third generation epidermal growth factor receptor tyrosine kinase inhibitors in the treatment efficacy and adverse events: A Bayesian meta-analysis","volume":"12","author":"Yu","year":"2025","journal-title":"Glob. Med. Genet."},{"key":"10.1016\/j.tice.2026.103700_bib29","article-title":"Imaging Non-small cell lung cancer EGFR Del19 and L858R with radiolabeled small molecule","volume":"14","author":"Fawwaz","year":"2024","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib30","doi-asserted-by":"crossref","DOI":"10.3390\/ph16040534","article-title":"Structure-activity relationship studies based on quinazoline derivatives as EGFR Kinase Inhibitors (2017-Present)","volume":"16","author":"\u0218andor","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.tice.2026.103700_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.rechem.2024.101615","article-title":"Covalent drug \u2013 an emerging framework for targeted drug development","volume":"8","author":"Bhole","year":"2024","journal-title":"Results Chem."},{"key":"10.1016\/j.tice.2026.103700_bib32","article-title":"Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors","volume":"2","author":"Du","year":"2021","journal-title":"Innovation"},{"key":"10.1016\/j.tice.2026.103700_bib33","first-page":"91","article-title":"Profile of rociletinib and its potential in the treatment of non-small-cell lung cancer","volume":"7","author":"Tran","year":"2016","journal-title":"Lung Cancer"},{"key":"10.1016\/j.tice.2026.103700_bib34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1146\/annurev-physiol-022516-034125","article-title":"The Sodium\/Iodide Symporter (NIS): molecular physiology and preclinical and clinical applications","volume":"79","author":"Ravera","year":"2017","journal-title":"Annu. Rev. Physiol."},{"key":"10.1016\/j.tice.2026.103700_bib35","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1021\/acs.jmedchem.1c01211","article-title":"Development of radiohalogenated osimertinib derivatives as imaging probes for companion diagnostics of osimertinib","volume":"65","author":"Mishiro","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib36","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1007\/s00259-007-0636-6","article-title":"Evaluation of [18F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors","volume":"35","author":"Su","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.tice.2026.103700_bib37","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/s11307-010-0408-8","article-title":"Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA\u2014a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas","volume":"13","author":"Pal","year":"2011","journal-title":"Mol. Imaging Biol."},{"key":"10.1016\/j.tice.2026.103700_bib38","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/1759-7714.13430","article-title":"CM082, a novel angiogenesis inhibitor, enhances the antitumor activity of gefitinib on epidermal growth factor receptor mutant non-small cell lung cancer in vitro and in vivo","volume":"11","author":"Zhang","year":"2020","journal-title":"Thorac. Cancer"},{"key":"10.1016\/j.tice.2026.103700_bib39","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1128\/AAC.46.3.834-840.2002","article-title":"Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate","volume":"46","author":"Bekersky","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tice.2026.103700_bib40","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11095-018-2561-8","article-title":"QSAR development for plasma protein binding: influence of the ionization state","volume":"36","author":"Toma","year":"2018","journal-title":"Pharm. Res."},{"key":"10.1016\/j.tice.2026.103700_bib41","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241289648","article-title":"Expert consensus on the use of third-generation EGFR-TKIs in EGFR-mutated advanced non-small cell lung cancer with various T790M mutations post-resistance to first-\/second-generation EGFR-TKIs","volume":"16","author":"Ma","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"key":"10.1016\/j.tice.2026.103700_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108861","article-title":"Chalcone-inspired indole, carbazole, and phenothiazine hybrids as potent aldose reductase inhibitors with selective anticancer potential: Rational design, synthesis, and multi-level characterization","volume":"164","author":"G\u00fcle\u00e7","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib43","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1016\/j.nucmedbio.2014.06.005","article-title":"Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors","volume":"41","author":"Slobbe","year":"2014","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.tice.2026.103700_bib44","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.3389\/fbioe.2026.1741512","article-title":"Synthesis, radiolabeling, and evaluation of a 68Ga-labeled tyrosine kinase inhibitor for detecting EGFRT790M mutations in vivo","volume":"14","author":"Xie","year":"2026","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/j.tice.2026.103700_bib45","article-title":"Radiolabeled EGFR Tyrosine Kinase for the Detection of Dual Mutations EGFR L858R\/T790M in NSCLC","volume":"13","author":"Fawwaz","year":"2023","journal-title":"Biointerface Res. Appl. Chem."},{"key":"10.1016\/j.tice.2026.103700_bib46","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1002\/jlcr.3771","article-title":"Identifying nonsmall-cell lung tumours bearing the T790M EGFR TKI resistance mutation using PET imaging","volume":"62","author":"Goggi","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.tice.2026.103700_bib47","doi-asserted-by":"crossref","DOI":"10.3390\/life12060897","article-title":"Multidrug resistance of cancer cells and the vital role of P-Glycoprotein","volume":"12","author":"Karthika","year":"2022","journal-title":"Life"},{"key":"10.1016\/j.tice.2026.103700_bib48","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13071103","article-title":"Pharmaceutical formulations with P-glycoprotein inhibitory effect as promising approaches for enhancing oral drug absorption and bioavailability","volume":"13","author":"Nguyen","year":"2021","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.tice.2026.103700_bib49","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jctb.70146","article-title":"Nanoscale zinc oxide (ZnO NPs)\u2013alginate\u2013PEG\u2013activated carbon nanocomposite for efficient Cr(VI) removal from electroplating wastewater: adsorption isotherms and eco-toxicity evaluation","volume":"101","author":"Lavanya","year":"2026","journal-title":"J. Chem. Technol. Biotechnol."},{"key":"10.1016\/j.tice.2026.103700_bib50","doi-asserted-by":"crossref","DOI":"10.1002\/ffj.70088","article-title":"Green nanoemulsion formulation of citrus hystrix essential oil: characterisation, biological potentials, and eco\u2013biocompatibility profiling","author":"Raj","year":"2026","journal-title":"Flavour. Fragr. J."}],"container-title":["Tissue and Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626003940?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040816626003940?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T20:21:33Z","timestamp":1789244493000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040816626003940"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":50,"alternative-id":["S0040816626003940"],"URL":"https:\/\/doi.org\/10.1016\/j.tice.2026.103700","relation":{},"ISSN":["0040-8166"],"issn-type":[{"value":"0040-8166","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanistic insights into EGFR-Targeted: [\u00b9\u00b2\u2075I]I-rociletinib as a model small-molecule radioligand","name":"articletitle","label":"Article Title"},{"value":"Tissue and Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tice.2026.103700","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103700"}}